摘要
目的:探讨艾迪注射液联合FOLFOX-4方案化疗治疗晚期结直肠癌的效果及安全性。方法:选择2022年1月至2023年8月我院收治的60例晚期结直肠癌患者,采用随机数字表法分为对照组和研究组,各30例。对照组采用FOLFOX-4方案化疗,研究组在FOLFOX-4方案化疗基础上予艾迪注射液静脉滴注。比较2组临床疗效、不良反应,以及治疗前后免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)和NK细胞)和血清肿瘤标志物癌胚抗原(CEA)、糖链抗原19-9(CA19-9)、糖链抗原242(CA242)水平。结果:研究组疾病控制率及疾病缓解率均高于对照组,P<0.05。治疗后研究组CD4^(+)、CD4^(+)/CD8^(+)、NK细胞比率均高于对照组,CD8^(+)低于对照组(P<0.05)。治疗后研究组CEA、CA19-9、CA242水平均低于对照组,P<0.05。研究组血液学毒性事件、消化系统反应、感觉性神经病变发生率均低于对照组,P<0.05。结论:艾迪注射液联合FOLFOX-4方案化疗治疗晚期结直肠癌可提高临床治疗效果,调节患者免疫功能,降低其血清肿瘤标志物水平及不良反应发生风险。
Objective To investigate the efficacy and safety of Aidi Injection combined with FOLFOX-4 chemotherapy in the treatment of advanced colorectal cancer.Methods Total 60 patients with advanced colorectal cancer admitted to our hospital from January 2022 to August 2023 were selected and divided into control group and study group by random number table method,with 3o cases in each group.The control group was given FOLFOX-4 chemotherapy regimen,and the study group was given Addy Injection on the basis of FOLFOX-4 chemotherapy regimen.The clinical efficacy,adverse reactions,immune function indicators(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and NK cells)and serum tumor markers of carcinoembryonic antigen(CEA),glycoantigen 19-9(CA19-9)and glycoantigen 242(CA242)were compared between the two groups.Results The disease control rate and remission rate of the study group were higher than those of the control group(P<0.05).After treatment,the cell ratios of CD4^(+),CD4^(+)/CD8^(+),NK in the study group were higher than those in the control group,and CD8+in the study group was lower than that in the control group(P<0.05).After treatment,levels of CEA,CA19-9 and CA242 in the study group were lower than those in the control group(P<0.05).The incidence of hematological toxicity,digestive system reaction and sensory neuropathy in the study group was lower than that in the control group(P<0.05).Conclusion Aidi Injection combined with FOLFOX-4 chemotherapy regimen in the treatment of advanced colorectal cancer can improve clinical efficacy,regulate the immune function of patients,reduce the levels of serum tumor markers and the risk of adverse reactions.
作者
李欣
夏春磊
LI Xin;XIA Chun-lei(Department of Pharmacy,Third Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473000;Department of Gastroenterology and Oncology,Third Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473000)
出处
《中国肛肠病杂志》
2024年第5期30-32,共3页
Chinese Journal of Coloproctology
